This site is intended for healthcare professionals
Drug information


Read time: 15 mins
Last updated: 06 May 2020
Published: 24 Jul 2020

4.1 Therapeutic indications

Flecainide acetate is indicated for use in patients with the following arrhythmias:

Severe symptomatic supraventricular arrhythmia

AV nodal reciprocating tachycardia.

Arrhythmias associated with the Wolff-Parkinson-White syndrome and similar conditions associated with the presence of accessory pathways.

Paroxysmal atrial fibrillation in patients with disabling symptoms after cardioversion.

Patients with structural heart disease and/or impaired left ventricular function should be excluded because of the increased risk of pro-arrhythmic effects. Arrhythmias of recent onset will respond more readily.

Symptomatic sustained ventricular tachycardia.

Premature ventricular contractions and/or non-sustained ventricular tachycardia which are causing disabling symptoms which have failed to respond to other forms of therapy or in which other treatments have not been tolerated.

Flecainide tablets can be used for the maintenance of normal rhythm following conversion by other means.

Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.




The drug SPC information (indications, contra-indications, interactions, etc), has been developed in collaboration with eMC ( Medthority offers the whole library of SPC documents from eMC.

Medthority will not be held liable for explicit or implicit errors, or missing data.

Reporting of suspected adverse reactions 

Drug Licencing

Drugs appearing in this section are approved by UK Medicines & Healthcare Products Regulatory Agency (MHRA), & the European Medicines Agency (EMA).